IP Library Granted Patent US 12,205,698
Granted Patent B2
US 12,205,698 · App. 18/426,250 · Granted Jan 21, 2025

Advising diabetes medications

Inventors: Robert C. Booth (Greer, SC); Andrew Rhinehart (Greenville, SC); Harry Hebblewhite (Atlanta, GA)
Assignee: Aseko, Inc.
G16H20/13G16H10/60G16H20/17G16H40/63G16H50/20G16H50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,205,698
App. No.
18/426,250
Granted
Jan 21, 2025
Kind
B2
Abstract

A method includes obtaining prescribing drug information and published guidelines for each of a plurality of ADMs available for managing glucose levels, and receiving patient information associated with a patient. The method also includes ordering total demerit values from lowest to highest, selecting a predetermined number of recommended ADMs associated with the lowest total demerit values, and determining a recommended dosage for each recommended ADM. The method also includes transmitting a therapy regimen to a patient device associated with the patient. The therapy regimen includes the recommended ADMs and the recommended dosage for each recommended ADM.

Claims (96)

1. A computer-implemented method executed on data processing hardware that causes the data processing hardware to perform operations comprising:

receiving patient information associated with a patient seeking selection and dosing of one or more of a plurality of available Anti-Diabetes Medications (ADMs) for managing glucose levels;

obtaining treatment guideline ratings each assigned by the patient that measures a subjective level of importance to the patient for a corresponding treatment guideline;

obtaining prescribing drug information and published guidelines for each of the plurality of available ADMs;

for each corresponding available ADM of the plurality of available ADMs:

obtaining scaled guideline values for the corresponding available ADM based on the prescribing drug information and the published guidelines, each scaled guideline value associated with a corresponding treatment guideline rating;

determining a guideline demerit numerical value for the corresponding available ADM by multiplying, for each treatment guideline rating, the treatment guideline rating times the corresponding scaled guideline value and a guideline demerit increment value; and

determining a total demerit value for the corresponding available ADM based on the guideline demerit numerical value determined for the corresponding available ADM;

ordering the total demerit numerical values in numerical order for the available ADMs from the lowest total demerit numerical value to the highest total demerit numerical value;

selecting a predetermined number of recommended ADMs associated with the lowest total numerical demerit values from the plurality of available ADMs;

determining a recommended dosage for each recommended ADM based on the patient information, the prescribing drug information, and the published guidelines; and

transmitting, via a network, instructions to an administration device associated with one of the recommended ADMs, the instructions when received by the administration device causing the administration device to configure a doser of the administration device to administer the recommended dosage of the one of the recommended ADMs to the patient.

2. The computer-implemented method of claim 1 , wherein the patient information comprises:

a current medications list including a list of medications and corresponding dosages the patient is currently prescribed; and

medical conditions associated with the patient.

3. The computer-implemented method of claim 2 , wherein the patient information further comprises at least one of:

a target glucose range for the patient;

a target A1c value for the patient;

a preferred minimum monthly treatment cost; or

a preferred maximum monthly treatment cost.

4. The computer-implemented method of claim 2 , wherein the patient information further comprises:

one or more glucose values for the patient measured by a glucometer or continuous glucose monitor in communication with the data processing hardware; or

an A1c value for the patient.

5. The computer-implemented method of claim 1 , wherein the treatment guideline ratings comprise at least one of:

a cost rating;

a body weight rating;

a treatment regimen complexity rating;

a treatment efficacy rating;

a mealtime coverage needs rating; or

a hypoglycemia rating.

6. The computer-implemented method of claim 1 , wherein the prescribing drug information and published guidelines comprises, for each corresponding available ADM of the plurality of available ADMs:

one or more contraindicating conditions associated with the corresponding available ADM; and

a list of medications that interact with the corresponding available ADM.

7. The computer-implemented method of claim 6 , wherein the operations further comprise, for each corresponding available ADM of the plurality of available ADMs:

assigning an adverse demerit increment value when the medical conditions associated with the patient indicate that the patient currently has any of the contraindicating conditions associated with the corresponding available ADM; and

assigning the adverse demerit increment value when the current medications list indicate that the patient is currently taking at least one of the medications that interact with corresponding available ADM,

wherein determining the total demerit numerical value for the corresponding available ADM is further based on a sum of each adverse demerit increment value assigned to the corresponding available ADM.

8. The computer-implemented method of claim 1 , wherein the operations further comprise:

receiving exercise data from a fitness tracker associated with the patient; and

adjusting the recommended dosage for at least one of the recommended ADMs based on the received exercise data.

9. The computer-implemented method of claim 1 , wherein the operations further comprise:

obtaining a list of excluded ADMs that the patient is either allergic to or is excluded from the treatment regimen for the patient; and

for at least one corresponding available ADM of the plurality of available ADMs:

determining the corresponding available ADM is on the list of excluded ADMs; and

assigning a high modified demerit numerical value to the corresponding available ADM; and

replacing the total demerit numerical value for the corresponding available ADM with the assigned high modified demerit value.

10. The computer-implemented method of claim 1 , wherein the operations further comprise transmitting a therapy regimen from the data processing hardware to a patient device associated with the patient and in communication with the data processing hardware via the network, the therapy regimen comprising the recommended ADMs and the recommended dosage for each recommended ADM, the therapy regimen when received by the patient device causing the patient device to display the recommended ADMs and the recommended dosage for each recommended ADM on a patient interface executing on the patient device.

11. A system comprising:

data processing hardware; and

memory hardware in communication with the data processing hardware and storing instructions that when executed on the data processing hardware causes the data processing hardware to perform operations comprising:

receiving patient information associated with a patient seeking selection and dosing of one or more of a plurality of available Anti-Diabetes Medications (ADMs) for managing glucose levels;

obtaining treatment guideline ratings each assigned by the patient that measures a subjective level of importance to the patient for a corresponding treatment guideline;

obtaining prescribing drug information and published guidelines for each of the plurality of available ADMs;

for each corresponding available ADM of the plurality of available ADMs:

obtaining scaled guideline values for the corresponding available ADM based on the prescribing drug information and the published guidelines, each scaled guideline value associated with a corresponding treatment guideline rating;

determining a guideline demerit numerical value for the corresponding available ADM by multiplying, for each treatment guideline rating, the treatment guideline rating times the corresponding scaled guideline value and a guideline demerit increment value; and

determining a total demerit value for the corresponding available ADM based on the guideline demerit numerical value determined for the corresponding available ADM;

ordering the total demerit numerical values in numerical order for the available ADMs from the lowest total demerit numerical value to the highest total demerit numerical value;

selecting a predetermined number of recommended ADMs associated with the lowest total numerical demerit values from the plurality of available ADMs;

determining a recommended dosage for each recommended ADM based on the patient information, the prescribing drug information, and the published guidelines; and

transmitting, via a network, instructions to an administration device associated with one of the recommended ADMs, the instructions when received by the administration device causing the administration device to configure a doser of the administration device to administer the recommended dosage of the one of the recommended ADMs to the patient.

12. The system of claim 11 , wherein the patient information comprises:

a current medications list including a list of medications and corresponding dosages the patient is currently prescribed; and

medical conditions associated with the patient.

13. The system of claim 12 , wherein the patient information further comprises at least one of:

a target glucose range for the patient;

a target A1c value for the patient;

a preferred minimum monthly treatment cost; or

a preferred maximum monthly treatment cost.

14. The system of claim 12 , wherein the patient information further comprises:

one or more glucose values for the patient measured by a glucometer or continuous glucose monitor in communication with the data processing hardware; or

an A1c value for the patient.

15. The system of claim 11 , wherein the treatment guideline ratings comprise at least one of:

a cost rating;

a body weight rating;

a treatment regimen complexity rating;

a treatment efficacy rating;

a mealtime coverage needs rating; or

a hypoglycemia rating.

16. The system of claim 11 , wherein the prescribing drug information and published guidelines comprises, for each corresponding available ADM of the plurality of available ADMs:

one or more contraindicating conditions associated with the corresponding available ADM; and

a list of medications that interact with the corresponding available ADM.

17. The system of claim 16 , wherein the operations further comprise, for each corresponding available ADM of the plurality of available ADMs:

assigning an adverse demerit increment value when the medical conditions associated with the patient indicate that the patient currently has any of the contraindicating conditions associated with the corresponding available ADM; and

assigning the adverse demerit increment value when the current medications list indicate that the patient is currently taking at least one of the medications that interact with corresponding available ADM,

wherein determining the total demerit numerical value for the corresponding available ADM is further based on a sum of each adverse demerit increment value assigned to the corresponding available ADM.

18. The system of claim 11 , wherein the operations further comprise:

receiving exercise data from a fitness tracker associated with the patient; and

adjusting the recommended dosage for at least one of the recommended ADMs based on the received exercise data.

19. The system of claim 11 , wherein the operations further comprise:

obtaining a list of excluded ADMs that the patient is either allergic to or is excluded from the treatment regimen for the patient; and

for at least one corresponding available ADM of the plurality of available ADMs:

determining the corresponding available ADM is on the list of excluded ADMs; and

assigning a high modified demerit numerical value to the corresponding available ADM; and

replacing the total demerit numerical value for the corresponding available ADM with the assigned high modified demerit value.

20. The system of claim 11 , wherein the operations further comprise transmitting a therapy regimen from the data processing hardware to a patient device associated with the patient and in communication with the data processing hardware via the network, the therapy regimen comprising the recommended ADMs and the recommended dosage for each recommended ADM, the therapy regimen when received by the patient device causing the patient device to display the recommended ADMs and the recommended dosage for each recommended ADM on a patient interface executing on the patient device.

Continuity (5)
Continuation 18352046 · Jul 13, 2023
Continuation 18089380 · Dec 27, 2022
Continuation 16222415 · Dec 17, 2018
Provisional Application 62609326 · Dec 21, 2017
Related Publication 20240170123A1 · May 23, 2024
References Cited (17)
US 20070179434A1 · Weinert et al. · 2007 [cited by applicant]
US 20080306353A1 · Douglas · 2008 [cited by examiner]
US 20090171697A1 · Glauser et al. · 2009 [cited by applicant]
US 20100138453A1 · Alferness · 2010 [cited by examiner]
US 20100198020A1 · Alferness · 2010 [cited by examiner]
US 20100292634A1 · Kircher, Jr. · 2010 [cited by examiner]
US 20120286953A1 · Bousamra · 2012 [cited by examiner]
US 20130317316A1 · Kandeel · 2013 [cited by examiner]
US 20140032196A1 · Albisser · 2014 [cited by examiner]
US 20140181128A1 · Riskin · 2014 [cited by examiner]
US 20160324481A1 · Christensen et al. · 2016 [cited by applicant]
US 20170053101A1 · Booth et al. · 2017 [cited by applicant]
US 20170232204A1 · Knapp · 2017 [cited by examiner]
US 20170242962A1 · Lenchitsky · 2017 [cited by applicant]
US 20170286638A1 · Searle · 2017 [cited by examiner]
US 20180353698A1 · Saint · 2018 [cited by examiner]
International Search Report and Written Opinion for the related application No. PCT/US2018/066025 dated Apr. 18, 2019. [cited by applicant]